BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The Welsh Blood Service (WBS) is seeking to engage with the market regarding the future procurement of an advanced automated haematology analysis system to support blood donor assessment, blood component quality monitoring, research and innovation activities. The proposed solution will be required to provide automated full blood count (FBC) analysis, 5-part white cell differential capability and integrated reticulocyte analysis on the primary analyser. Of particular interest are systems capable of generating the data required to support emerging donor health assessment methodologies, including FlowScore calculation and reticulated haemoglobin analysis for the early detection of iron deficiency in blood donors.
The future requirement is expected to include advanced analytical capabilities that support the unique operational needs of a blood establishment. These include fluorescence platelet counting with high accuracy at low platelet concentrations, reticulated platelet measurement, low-level white cell enumeration suitable for blood component quality monitoring, and the ability to perform blood component testing without the need for separate instrumentation. Suppliers should be able to demonstrate how their platforms support routine blood component quality control programmes through dedicated blood bank functionality and provide evidence of successful implementation within blood services, blood centres or comparable blood establishments.
WBS is particularly interested in solutions that are supported by robust External Quality Assessment (EQA/EQAS) programmes and can demonstrate meaningful peer group benchmarking through sufficient participant numbers using the same analyser platform and methodology. Suppliers should be able to demonstrate compliance with applicable medical device regulations, support quality and regulatory requirements through a mature quality management system and provide resilient service and maintenance arrangements that minimise downtime and ensure continuity of critical testing services.
This notice is intended to inform the market of WBS's future requirements and to encourage engagement from suppliers capable of supporting the evolving needs of blood donor care, blood component quality assurance and transfusion medicine research.
Interested parties are invited to email …@wales.nhs.uk with details of their suitable analyser by Tuesday 8th August 2026. We may engage further with interested parties once responses have been received.
Preliminary market engagement notice (UK2). The buyer wants to talk to suppliers before designing the procurement. Taking part is how to shape it.
Bids are submitted through the buyer’s own portal, not on this site. Read the full notice on Find a Tender before relying on any date here.
No supplier information available.
This procurement was divided into 1 lots, each awarded separately.
| Lot | Value | Status |
|---|---|---|
| Lot 1 Apr 2027 – Mar 2032 | - | planning |